logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5993.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5993.produseast1
Yellow fever | Collections | MSF Science Portal
Yellow fever

Yellow fever

Collection Content

Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (9)
  • CSV
  • BibTeX
  • EndNote
Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (9)
  • CSV
  • BibTeX
  • EndNote

See more collections

Safe abortion care at MSF

Safe abortion care at MSF

Unsafe abortion is a major cause of maternal death, and the only one that is completely preventable. Yet over 30 million unsafe abortions occur each year, leading to at least 29,000 deaths and millions of serious complications—nearly all in low- and middle-income countries. MSF teams see these tragic consequences first-hand, treating thousands of patients every year with severe, potentially life-threatening effects from unsafe abortion.


To mark International Safe Abortion Awareness Day (28 September 2024), this Collection presents highlights of MSF’s work on safe abortion care (SAC) as a way to reduce maternal death and injury. By re-assessing and reshaping how our projects deliver SAC in fragile and conflict-affected settings, we have been able to significantly expand services in those contexts and across MSF projects globally. In parallel, we also conducted in-depth studies of abortion complications and their contributing factors in fragile settings, where a dearth of evidence limits understanding of women's needs in accessing comprehensive care. These findings are helping to identify gaps in service delivery and inform operational decision-making.

The endTB project

The endTB project

The endTB project aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF. This collection contains the final and intermediate results of the studies, advocacy reports, and study presentations. For more information about the endTB project, visit https://endtb.org/.

New tools and approaches to drug-resistant TB

New tools and approaches to drug-resistant TB
View All Collections
The World Health Organization estimates that 410,000 people developed a drug-resistant tuberculosis infection (DR-TB) in 2022, only 40% of whom were diagnosed and started on treatment—and only 63% then cured. Given all these points of failure, innovation in preventing, diagnosing and treating DR-TB cannot come fast enough. To mark World TB Day (24 March 2024) the content collection linked below highlights recent work by MSF and collaborators to help change this grim picture. The TB-PRACTECAL and endTB studies delivered robust evidence for shorter, safer, more effective drug regimens that are already saving lives worldwide. Other studies explore new approaches to preventive treatment and simpler, quicker, accurate detection of TB and drug resistance—especially among difficult-to-diagnose populations such as children and people living with HIV. But to impact DR-TB globally these innovations must become widely accessible. This requires changes on many fronts, as described in an accompanying Collection (Expanding Access to Lifesaving New TB Tools).
Journal Article
|
Commentary

Yellow fever resurgence: An avoidable crisis?

Lindsey NP, Horton J, Barrett ADT, Demanou M, Monath TP,  et al.
2022-11-02 • NPJ Vaccines
2022-11-02 • NPJ Vaccines
Journal Article
|
Research

Missed opportunities for vaccination (MOV) in children up to 5 years old in 19 Médecins Sans Frontières-supported health facilities: a cross-sectional survey in six low-resource countries

Borras-Bermejo B, Panunzi I, Bachy C, Gil-Cuesta J
2022-07-26 • BMJ Open
2022-07-26 • BMJ Open
OBJECTIVE
To describe missed opportunities for vaccination (MOV) among children visiting Médecins Sans Frontières (MSF)-supported facilities, their related factors, and to identify r...
Conference Material
|
Video

Immunogenicity of fractional dose yellow fever vaccine in children and HIV+ adults

Namulwana ML
2022-06-21 • Epicentre Scientific Day Paris 2022
2022-06-21 • Epicentre Scientific Day Paris 2022
Journal Article
|
Research

Metagenomic sequencing characterizes a wide diversity of viruses in field mosquito samples in Nigeria

Oguzie JU, Nwangwu UC, Oluniyi PE, Olumade TJ, George UE,  et al.
2022-05-10 • Scientific Reports
2022-05-10 • Scientific Reports
Mosquito vectors are a tremendous public health threat. One in six diseases worldwide is vector-borne transmitted mainly by mosquitoes. In the last couple of years, there have been activ...
Journal Article
|
Pre-Print

The burden of vaccine hesitancy for routine immunization in Yaounde-Cameroon: restrictive sampling technique

Yakum MN, Funwie AD, Ajong AB, Tsafack M, Ebaze LE,  et al.
2022-02-21 • medRxiv
2022-02-21 • medRxiv
Immunization is the most cost-effective health intervention in the world yet, vaccination uptake is still low with less than 50% of children aged 12-23 months fully vaccinated Cameroon. ...
Conference Material
|
Video

Fractional dosing of vaccines: when less could mean more

Juan A
2021-06-10 • Epicentre Scientific Day Paris 2021
2021-06-10 • Epicentre Scientific Day Paris 2021
Journal Article
|
Research

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial

Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P,  et al.
2021-01-09 • Lancet
2021-01-09 • Lancet
BACKGROUND
Stocks of yellow fever vaccine are insufficient to cover exceptional demands for outbreak response. Fractional dosing has shown efficacy, but evidence is limited to the 17...
Journal Article
|
Research

Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons—Liberia, 2004

Huhn GD, Brown J, Perea W, Berthe A, Otero H,  et al.
2006-02-06 • Vaccine
2006-02-06 • Vaccine
Yellow fever (YF) is a mosquito-borne vaccine-preventable disease with high mortality. In West Africa, low population immunity increases the risk of epidemic transmission. A cluster surv...
Journal Article
|
Letter

Shortage of vaccines during a yellow fever outbreak in Guinea

Nathan N, Barry M, Van Herp M, Zeller H
2001-12-01 • Lancet
2001-12-01 • Lancet
A yellow fever epidemic erupted in Guinea in September, 2000. From Sept 4, 2000, to Jan 7, 2001, 688 instances of the disease and 225 deaths were reported. The diagnosis was laboratory c...